See more : Banco Bradesco S.A. (BBDC3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Millendo Therapeutics, Inc. (MLND) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Millendo Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Plug Power Inc. (PLUN.DE) Income Statement Analysis – Financial Results
- Grainger plc (GRGTF) Income Statement Analysis – Financial Results
- Bitcoin Group SE (ADE.DE) Income Statement Analysis – Financial Results
- Integrated Wind Solutions ASA (IWS.OL) Income Statement Analysis – Financial Results
- Arm Holdings plc American Depositary Shares (ARM) Income Statement Analysis – Financial Results
Millendo Therapeutics, Inc. (MLND)
About Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 295.00K | 653.00K | 277.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 790.00K | 5.40M | 2.25M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -495.00K | -4.75M | -1.97M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -167.80% | -727.11% | -711.91% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.37M | 27.84M | 14.43M | 18.34M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M |
| General & Administrative | 15.60M | 17.56M | 12.45M | 0.00 | 0.00 | 0.00 | 0.00 | 13.33M | 7.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.60M | 17.56M | 12.45M | 0.00 | 0.00 | 0.00 | 0.00 | 13.33M | 7.21M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 27.74M | 49.22M | 51.59M | 26.15M | 0.00 | 0.00 |
| Operating Expenses | 35.97M | 45.40M | 26.87M | 46.08M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M |
| Cost & Expenses | 35.97M | 45.40M | 26.87M | 46.87M | 76.27M | 72.28M | 47.93M | 29.13M | 13.53M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | -1.04M | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.10M | 1.05M | 32.00K | 1.65M | 2.24M | 1.29M | 450.00K | 231.00K | 93.00K |
| EBITDA | -35.30M | -44.55M | -27.03M | -49.26M | -79.82M | -71.86M | -49.07M | -28.81M | -13.42M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -16,697.63% | -12,223.74% | -25,941.52% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.97M | -45.40M | -26.87M | -46.58M | -75.61M | -72.00M | -47.93M | -29.13M | -13.53M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -15,788.47% | -11,579.17% | -25,992.42% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -434.00K | 831.00K | -303.00K | -4.33M | -6.45M | -1.15M | -1.59M | 90.00K | 19.00K |
| Income Before Tax | -36.41M | -44.57M | -27.18M | -50.91M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -17,256.95% | -12,566.46% | -26,405.78% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -434.00K | -207.00K | -169.00K | 67.00K | 201.00K | 75.00K | -1.59M | 90.00K | 19.00K |
| Net Income | -36.41M | -44.57M | -27.19M | -50.98M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -17,279.66% | -12,597.24% | -26,432.85% | 0.00% | 0.00% | 0.00% |
| EPS | -28.95 | -48.77 | -263.65 | -321.49 | -575.72 | -608.24 | -491.98 | -404.39 | -523.20 |
| EPS Diluted | -28.95 | -48.77 | -263.65 | -321.49 | -575.72 | -608.24 | -491.98 | -404.39 | -523.20 |
| Weighted Avg Shares Out | 1.26M | 913.79K | 103.14K | 158.56K | 142.88K | 120.38K | 100.65K | 71.82K | 25.82K |
| Weighted Avg Shares Out (Dil) | 1.26M | 913.79K | 103.14K | 158.56K | 142.88K | 120.38K | 100.65K | 71.82K | 25.82K |
Millendo Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide in Patients with Prader-Willi Syndrome (PWS)
Millendo’s Julia Owens on leadership in rare diseases -
Source: https://incomestatements.info
Category: Stock Reports